- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
Patent holdings for IPC class C07D 237/04
Total number of patents in this class: 141
10-year publication summary
|
10
|
11
|
9
|
8
|
10
|
8
|
8
|
5
|
10
|
5
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Broad Institute, Inc. | 1990 |
10 |
| Araxes Pharma LLC | 90 |
6 |
| Dana-Farber Cancer Institute, Inc. | 2671 |
6 |
| Lantheus Medical Imaging, Inc. | 165 |
5 |
| Eonhf, Inc. | 45 |
5 |
| Bayer AG | 3553 |
4 |
| Bayer Pharma AG | 1005 |
4 |
| The General Hospital Corporation | 4890 |
4 |
| Massachusetts Institute of Technology | 10305 |
3 |
| JSR Corporation | 2553 |
3 |
| Chugai Seiyaku Kabushiki Kaisha | 1426 |
3 |
| Otsuka Pharmaceutical Co., Ltd. | 1510 |
3 |
| Revolution Medicines, Inc. | 337 |
3 |
| Theravance Biopharma R&D IP, LLC | 359 |
3 |
| Hoffmann-La Roche Inc. | 3841 |
2 |
| Boehringer Ingelheim International GmbH | 4479 |
2 |
| Syngenta Participations AG | 1479 |
2 |
| Anhui New Star Pharmaceutical Development Co., Ltd. | 13 |
2 |
| FMC Corporation | 815 |
2 |
| Medivir AB | 112 |
2 |
| Other owners | 67 |